Triamcinolone Acetonide and Botulinum Toxin A in the Treatment of Upper Eyelid Retraction in Thyroid-Associated Ophthalmopathy: A Clinical Study

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2300077958

Enrollment

Unknown

Registered

2023-11-24

Start date

2022-06-02

Completion date

Unknown

Last updated

2023-11-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Thyroid associated ophthalmopathy

Interventions

Control group:Triamcinolone acetonide periorbital injection

Observation group:Botulinum toxin A levator muscle injection combined with triamcinolone acetonide periorbital injection

Eligibility

Sex/Gender

All

Age

18 Years to 40 Years

Inclusion criteria

Inclusion criteria: (1) retraction of upper eyelid in one or both eyes; (2) abnormal thyroid function but controlled by medical treatment; (3) age = 18 years old; (4) informed consent of patients.

Exclusion criteria

Exclusion criteria: (1) normal thyroid function with thin eyelid; (2) diplopia and limitation of extraocular muscle movement; (3) compressive optic neuropathy, eyelid insufficiency, corneal ulcer; (4) systemic glucocorticoid treatment; (5) active eyelid inflammation; (6) history of trauma and levator muscle complex operation; (7) pregnant and lactating women.

Design outcomes

Primary

Measure	Time frame
Marginal reflex distance(MRD1);Graine sign(GS);	—

Secondary

Measure	Time frame
Intraocular pressure;Complication;	—

Countries

China

Contacts

Public ContactSong Xiaoqing

Putian First Hospital

ptsxq@126.com+86 139 0691 1696

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026